Details for Patent: 9,828,606

Which drugs does patent 9,828,606 protect, and when does it expire?

Patent 9,828,606 protects OXLUMO and is included in one NDA.

This patent has twenty-nine patent family members in eighteen countries.

Summary for Patent: 9,828,606

Title:	Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Abstract:	This invention relates to compounds, compositions, and methods useful for reducing Glycolate Oxidase (HAO1) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
Inventor(s):	Brown; Bob D. (Littleton, MA), Dudek; Henryk T. (Wellesley, MA)
Assignee:	Dicerna Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:	15/616,254
Patent Claim Types: see list of patent claims	Compound;

Drugs Protected by US Patent 9,828,606

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Alnylam Pharms Inc	OXLUMO	lumasiran sodium	SOLUTION;SUBCUTANEOUS	214103-001	Nov 23, 2020		RX	Yes	Yes			Y	Y

International Family Members for US Patent 9,828,606

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014369850
Australia	2021201953
Canada	2935220
Cyprus	1124203
Denmark	3087184
Denmark	3581654
European Patent Office	3087184